# Ribociclib for HR-positive HER2-negative Metastatic Breast Cancer

> **NCT07164976** · PHASE1,PHASE2 · RECRUITING · sponsor: **Nagoya City University** · enrollment: 86 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Ribociclib 400mg
- **DRUG:** Ribociclib 600mg
- **DRUG:** Ribociclib 600mg

## Key facts

- **NCT ID:** NCT07164976
- **Lead sponsor:** Nagoya City University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-01
- **Primary completion:** 2029-09-01
- **Final completion:** 2030-04-01
- **Target enrollment:** 86 (ESTIMATED)
- **Last updated:** 2026-04-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07164976

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07164976, "Ribociclib for HR-positive HER2-negative Metastatic Breast Cancer". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT07164976. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*